Introduction: A 40-Year Standard Challenged
For more than four decades, beta-blockers have been a cornerstone of recovery after a heart attack. It is routine: a patient suffers a myocardial infarction, receives modern care—stents, statins, antiplatelet drugs—and then is discharged with a prescription for beta-blockers, often for life. This practice became standard in the 1980s and has remained largely unquestioned, supported by trials conducted before the era of routine reperfusion and potent medical therapies.
That paradigm just crumbled. The REBOOT trial—short for Treatment with Beta-Blockers after Myocardial Infarction without Reduced Ejection Fraction—has delivered results that could reshape international clinical guidelines. Led by senior investigator Dr. Valentin Fuster of Mount Sinai Fuster Heart Hospital and Spain's Centro Nacional de Investigaciones Cardiovasculares (CNIC), with Dr. Borja Ibáñez as principal investigator, this massive international study found that beta-blockers do not reduce death, recurrent heart attacks, or heart failure hospitalizations in patients whose hearts are still pumping normally after an uncomplicated heart attack.
Published simultaneously in The New England Journal of Medicine and The Lancet, and presented at the European Society of Cardiology Congress in Madrid, the REBOOT findings represent one of the most significant advances in heart attack treatment in decades. With over 8,500 patients followed for nearly four years, it is the largest trial ever to address this question.
The implications are staggering: more than 80 percent of patients with uncomplicated myocardial infarction are currently sent home on beta-blockers. If they derive no meaningful benefit, those medications could become unnecessary for a vast population, reducing pill burden, side effects, and healthcare costs. Yet the story is not entirely black and white—subgroup analyses hint at nuances, particularly for women and for patients with mildly reduced heart function.
This article dives deep into the REBOOT trial data, unpacking the numbers, the clinical context, and what it means for patients and doctors alike.
How the REBOOT Trial Was Conducted
The REBOOT trial was an investigator-initiated, randomized, open-label study with blinded endpoint assessment (PROBE design). It enrolled patients from 109 hospitals across Spain and Italy between 2020 and 2024. The trial was coordinated by CNIC in collaboration with the Mario Negri Institute in Milan, reflecting a truly international effort.
Eligibility Criteria
Participants had to have experienced a myocardial infarction (ST- or non-ST-elevation) and undergone invasive management during their index hospitalization. Crucially, they needed a predischarge left ventricular ejection fraction (LVEF) greater than 40% and no history or signs of heart failure. This focused on the population most likely to be prescribed beta-blockers under current guidelines despite lacking robust evidence—patients with preserved or only mildly reduced heart function.
Randomization and Follow-up
After giving informed consent, 8,505 patients were randomly assigned in a 1:1 ratio to either continue on beta-blocker therapy or to avoid beta-blockers entirely. Everyone in both groups otherwise received contemporary standard care, including statins, antiplatelet agents, and lifestyle counseling. The median follow-up was 3.7 years, allowing investigators to capture hard outcomes over a meaningful time horizon.
Baseline Characteristics
The study population had a mean age of 61 years, and 19.3% were women. At baseline, 10% had already suffered a prior myocardial infarction, and 12% were already taking beta-blockers before the index event—a reflection of real-world practice. These numbers matter because they ensure the trial's findings are applicable to the broad spectrum of patients cardiologists see today.
By randomly assigning such a large cohort and maintaining rigorous follow-up, REBOOT overcame the limitations of older trials that shaped the original beta-blocker guidelines. Those earlier studies were conducted before routine angiography, before stents, and before the modern pharmacopeia of cardioprotective drugs. REBOOT thus answers a pressing question: do beta-blockers still add value in the era of contemporary reperfusion and intensive medical therapy?
Primary Outcomes: No Meaningful Benefit
After a median follow-up of 3.7 years, the REBOOT trial delivered a clear message: beta-blocker therapy did not significantly reduce the risk of the primary composite endpoint compared with no beta-blocker therapy. The composite endpoint included all-cause death, nonfatal reinfarction (another heart attack), or hospitalization for heart failure.
The event rates per 1,000 patient-years were nearly identical:
| Outcome | Beta-blocker (per 1,000 py) | Control (per 1,000 py) | Hazard Ratio (95% CI) | p-value |
|---|---|---|---|---|
| Composite endpoint | 22.5 | 21.7 | 1.04 (0.89–1.22) | 0.63 |
| All-cause mortality | 11.2 | 10.5 | 1.06 (0.85–1.33) | NS |
| Nonfatal reinfarction | 10.2 | 10.1 | 1.01 (0.80–1.27) | NS |
| Heart failure admission | 2.7 | 3.0 | 0.89 (0.58–1.38) | NS |
The hazard ratio of 1.04 for the primary endpoint, with a 95% confidence interval ranging from 0.89 to 1.22 and a p-value of 0.63, indicates no statistically significant difference between the two groups. In plain terms: patients on beta-blockers fared about the same as those without. All confidence intervals comfortably cross 1, reinforcing the absence of a meaningful effect.
These results held across secondary outcomes as well. The fact that heart failure admission was slightly lower in the beta-blocker group (2.7 vs 3.0) but not significantly so (HR 0.89) further reinforces the null finding. The trial was adequately powered to detect clinically relevant differences, and none emerged.
With such a large sample and long follow-up, the REBOOT trial provides the most definitive answer to date on beta-blockers after uncomplicated myocardial infarction in patients with preserved ejection fraction. The answer is clear: no significant benefit.
Safety Signals and Subgroup Explorations
Beta-blockers are often prescribed because they are considered safe, but they are not free of side effects. The REBOOT trial captured safety outcomes rigorously. While the study was not powered to detect rare adverse events, some trends emerged that merit attention.
Safety Outcomes
Admission for stroke occurred slightly more often in the beta-blocker group (2.6 vs. 1.7 per 1,000 patient-years), yielding a hazard ratio of 1.50 with a 95% CI of 0.90–2.49. Although not statistically significant, the point estimate suggests a possible increased risk that could be clarified with larger studies or meta-analyses.
Symptomatic advanced atrioventricular (AV) block—a serious conduction disturbance—was similarly rare: 0.5 vs. 0.4 per 1,000 patient-years (HR 1.18, 95% CI 0.40–3.50). These numbers reaffirm that severe cardiac conduction side effects remain uncommon in this population.
Subgroup Analyses
The trial pre-specified several subgroups to look for hidden benefits. Across most strata—age, sex, presence of diabetes, prior MI, type of MI—beta-blockers showed no evidence of benefit. However, a hint of a signal appeared among patients with mildly reduced left ventricular ejection fraction (LVEF 40–49%). In that subgroup, fewer events were observed with beta-blockers, but the sample size was small, preventing firm conclusions.
That nuance aligns with clinical intuition: patients with some loss of contractile function might still derive classic beta-blocker benefits, whereas those with truly preserved function (>50%) likely do not. The REBOOT population was enriched for preserved function (about 70% of modern MI survivors), so the overall null result is driven by the majority.
Another notable subgroup finding involves gender. Women, as a whole, experienced more adverse events compared to men, and the pattern of beta-blocker effect differed between sexes. This led the investigators to launch a dedicated women’s substudy, published in the European Heart Journal, which we examine next.
Gender Differences and the Meta-Analysis
The Women’s Substudy
One of the most provocative findings from the REBOOT trial came from a prespecified subgroup analysis by sex. Women who received beta-blockers after a heart attack faced a higher risk of death, recurrent infarction, or heart failure hospitalization compared with women who did not receive the drugs. Men, by contrast, did not exhibit this increased risk.
Among women with preserved left ventricular ejection fraction (≥50%), the absolute risk difference was striking: 2.7% higher cumulative mortality over 3.7 years for those on beta-blockers versus those off. That translates to roughly 27 extra deaths per 1,000 women treated—a concerning signal given that beta-blockers have been considered benign. For women with mildly reduced EF (40–49%), the excess risk was not observed, suggesting the harm may be specific to those with fully preserved function.
Why might women respond differently? The biological underpinnings are not yet clear, but the finding underscores that one-size-fits-all prescribing is flawed. As Dr. Fuster noted, the trial “will reshape all international clinical guidelines,” and those guidelines will need to account for sex-specific nuances.
Meta-Analysis Confirms Benefit Only in Moderately Reduced EF
To bolster the evidence in the important mildly reduced EF subgroup (40–49%), the REBOOT team conducted a joint meta-analysis with three other recent trials: BETAMI, DANBLOCK, and CAPITAL-RCT. The results, published in The Lancet, included a total of 1,885 patients with mildly reduced LVEF: 991 assigned to beta-blockers and 894 to control.
The meta-analysis confirmed that beta-blockers significantly reduce the composite endpoint only in patients with moderately reduced contractile function (EF 40–49%). In those with preserved function (>50%), no benefit was seen—mirroring the overall REBOOT findings. This dichotomy suggests that the old paradigm, which treated all post-MI patients as a monolithic group, must be abandoned.
Visual: Patient Stratification by Ejection Fraction
Preserved EF
Mildly Reduced
Reduced
Note: REBOOT focused on the first two groups; the meta-analysis specifically addressed the 40–49% range.
Clinical Impact and What Comes Next
The REBOOT trial’s implications for everyday practice are profound. Currently, more than 80 percent of patients who suffer an uncomplicated myocardial infarction are discharged on beta-blockers, regardless of their heart function. If these drugs do not improve outcomes for the majority with preserved EF, that widespread prescribing represents a substantial opportunity to reduce polypharmacy, minimize side effects, and perhaps even improve patients' quality of life.
Beta-blockers are not without downsides. They can cause fatigue, bradycardia (slow heart rate), and sexual dysfunction—issues that can erode adherence and well-being, especially in patients who are already juggling multiple medications. Removing an unnecessary pill could make recovery simpler and less burdensome.
Limitations to Keep in Mind
Despite its strengths, REBOOT has limitations. The open-label design (though with blinded endpoint adjudication) could introduce bias, although objective outcomes like death and hospitalization are less susceptible. The event rates were relatively low, reflecting the improved prognosis of modern MI care; this is good news for patients but means that some subgroup analyses were underpowered. Most importantly, the trial’s findings apply specifically to patients with LVEF ≥40% and uncomplicated MI; they do not challenge the established benefit of beta-blockers in patients with severely reduced ejection fraction (≤40%), where robust evidence still supports their use.
Guideline Changes on the Horizon
As Dr. Ibáñez declared, “REBOOT will change clinical practice worldwide.” International guidelines are expected to be revised to restrict beta-blocker recommendations to those with reduced EF or perhaps those with mildly reduced EF where meta-analytic data hint at benefit. Shared decision-making will become more important: clinicians should discuss with patients the lack of clear benefit and the potential for harm, particularly in women with preserved function.
The trial also illustrates how medical dogma can persist long after the evidence base has become outdated. The original beta-blocker trials were landmark studies in their time, but medicine has evolved dramatically. REBOOT reminds us that continuous re-evaluation of standards is essential.
Conclusion
In the meantime, patients should not stop taking prescribed beta-blockers on their own. Any changes to medication regimens must be made in consultation with a cardiologist. However, the conversation has shifted—what was once a default prescription is now a choice that should be individualized based on ejection fraction, sex, and patient preferences.
The REBOOT trial stands as a testament to the power of rigorous, large-scale clinical research to overturn entrenched practices. For the tens of millions of heart attack survivors worldwide, the next chapter in their care may look quite different.
*This article was generated by AI based on research from multiple sources. While efforts are made to ensure accuracy, readers should verify information independently.*
Sources
- 1. ScienceDaily: "Common heart drug taken by millions found useless — and possibly dangerous" (2026-05-24) – Link
- 2. ESC Press Release: "Beta-blockers did not reduce cardiovascular events in selected heart attack patients in the REBOOT trial" (2025-08-30) – Link
- 3. CNIC: "NEJM & The Lancet: CNIC-led REBOOT clinical trial challenges 40-year-old standard of care for heart attack patients" – Link
- 4. EurekAlert: "CNIC-led REBOOT clinical trial challenges 40-year-old standard of care for heart attack patients" – Link
- 5. News-Medical: "REBOOT trial finds no benefit of beta blockers after uncomplicated heart attacks" – Link
- 6. SciTechDaily: "After 40 Years, Heart Doctors Say Beta Blockers May Do More Harm Than Good" – Link
- 7. HealthManagement: "REBOOT Trial: Beta-Blockers After Myocardial Infarction Without Reduced Ejection Fraction" – Link
- 8. The Lancet meta-analysis (via abstract): "β blockers after myocardial infarction with mildly reduced ejection fraction: a meta-analysis" – Link
Post a Comment